|
|
Volumn 1, Issue 3, 2006, Pages 217-235
|
|
Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTISENSE OLIGONUCLEOTIDE;
NUCLEOTIDE;
OBLIMERSEN;
PROTEIN BCL 2;
ACUTE GRANULOCYTIC LEUKEMIA;
B CELL LEUKEMIA;
BLOOD;
BREAST TUMOR;
CLINICAL TRIAL;
COLORECTAL TUMOR;
DOWN REGULATION;
DRUG COMBINATION;
DRUG EFFECT;
FEMALE;
HUMAN;
MALE;
MELANOMA;
METABOLISM;
METASTASIS;
NONHODGKIN LYMPHOMA;
PROSTATE TUMOR;
REVIEW;
SMALL CELL CARCINOMA;
BREAST NEOPLASMS;
CARCINOMA, SMALL CELL;
CLINICAL TRIALS AS TOPIC;
COLORECTAL NEOPLASMS;
DOWN-REGULATION;
DRUG THERAPY, COMBINATION;
FEMALE;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
LEUKEMIA, MYELOID, ACUTE;
LYMPHOMA, NON-HODGKIN;
MALE;
MELANOMA;
OLIGONUCLEOTIDES, ANTISENSE;
PROSTATIC NEOPLASMS;
PROTO-ONCOGENE PROTEINS C-BCL-2;
THIONUCLEOTIDES;
|
|
EID: 44849085132
PISSN: 15748871
EISSN: None
Source Type: Journal
DOI: 10.2174/157488706778250050 Document Type: Review |
|
Times cited : (60)
|
|
References (86)
|
